Assessment of cardiovascular risk in patients with primary chronic gout combined with metabolic syndrome
Journal Title: Міжнародний ендокринологічний журнал - Year 2019, Vol 15, Issue 4
Abstract
Background. The purpose of the study is to ivestigate the frequency of metabolic syndrome (MS) and to assess the total cardiovascular risk in patients with primary chronic gout, depending on the presence of MS. Materials and methods. Eighty-two patients with primary chronic gout, diagnosed with the qualification criteria of S.J. Wallase et al., were examined. The basic group included patients with primary chronic gout with MS (n = 52), which accounted for 63.4 % of all surveyed persons. The MS was diagnosed by IDF criteria. The comparison group involved patients with MS, matched by sex and age (n = 46). Clinical (anthropometric parameters, blood pressure) and laboratory examination (level of fasting glycaemia, uric acid, lipid, oral glucose tolerance test) took into account the presence of cardiovascular disease in medical history and its complications, evaluated cardiovascular risk on SCORE and PROCAM scales. Results. The incidence of obesity in the study groups was 65.4 and 63.0 %, respectively. The frequency of additional MS criteria was high in both groups studied. Hypertension and hypertriglyceridemia were equally often diagnosed in patients with MS regardless of the presence of gouty arthritis (p < 0.01). At least one additional MS criterion was detected in all those patients surveyed. 28.8 % of patients in the basic group and 4.3% patients in the comparison group were diagnosed with all five additional MS criteria (p < 0.01). In the patients of the basic group more than three additional MS criteria were identified compared to the comparison group — 51.9 and 30.4 %, respectively. The total cardiovascular risk on SCORE and PROCAM scales in patients in the basic group was significantly higher than in the comparison group (p < 0.05 and p < 0.01, respectively). Conclusions. MS was diagnosed in 63.4 % of patients with primary chronic gout. The patients with primary chronic gout combined with MS have a higher total cardiovascular risk on SCORE and PROCAM scales compared to patients with MS only. Evaluation of MS criteria, together with the assessment of cardiovascular risk, can be used in routine clinical practice to stratify patients with primary chronic gout who need lifestyle modifications and/or differentiated approaches to medical treatment.
Authors and Affiliations
A. O. Cherniaieva, M. R. Mykytyuk, Y. I. Karachentsev, N. O. Kravchun
Keywords
Related Articles
- EP ID EP630809
- DOI 10.22141/2224-0721.15.4.2019.174815
- Views 64
- Downloads 0
Cerebrovascular Disorders in Women with Overweight and Obesity
Cerebrоvascular diseases are one of the most maladaptive disorders in both men and women. Meanwhile, in the female population when compared to men, strokes occur much later. Strokes in women have higher incidence of trad...
Vitamin D — is everything as simple as it seems?
Even centuries after the discovery of vitamin D, there are gaps in understanding the role of its endocrine system. It is clear that vitamin D is important for stimulation of calcium absorption in the intestines in normal...
Pathogenetic Aspects of Preventive Correction of Cognitive Impairment in Metabolic Syndrome
Objective. To study the opportunities to increase the efficiency of pathogenetic therapy in patients with chronic cerebrovascular diseases (CVD) (discirculatory encephalopathy, DE) on the background of metabolic syndrome...
Diabetic Retinopathy: a New Approach to Drug Treatment
Diabetic retinopathy is a basic microvascular complication of diabetes and the leading cause of blindness in the adult population. A review of the literature on this pathology, a relatively new approach to medical treatm...
Correction of bone remodeling disorders in long-term corticosteroid therapy
Background. In severe dermatoses, corticosteroid drugs are usually prescribed for a long period of time, and even for life; therefore, the detection of side effects caused by prolonged use of systemic glucocorticosteroid...